Vaxcyte, Inc. (PCVX) Financial Statements (2026 and earlier)

Company Profile

Business Address 825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,661,427,0001,671,731,0001,747,208,0002,180,465,0001,452,697,0001,486,518,000
Cash and cash equivalent306,744,000346,850,000387,878,0001,050,189,000518,670,000611,512,000
Short-term investments1,354,683,0001,324,881,0001,359,330,0001,130,276,000934,027,000875,006,000
Receivables   20,262,00017,872,0008,470,00016,009,000
Prepaid expense   15,732,00010,588,0009,177,0007,774,000
Other current assets   4,456,0003,443,0001,376,0002,092,000
Other undisclosed current assets54,348,00044,832,000327,0001,497,0009,759,0004,679,000
Total current assets:1,715,775,0001,716,563,0001,787,985,0002,213,865,0001,481,479,0001,517,072,000
Noncurrent Assets
Operating lease, right-of-use asset85,649,00087,759,00072,102,00028,700,00026,779,00028,905,000
Property, plant and equipment242,266,000217,155,000198,045,000163,243,000125,973,00084,835,000
Long-term investments and receivables1,165,091,0001,279,031,0001,387,510,0001,092,574,000399,243,000413,247,000
Long-term investments1,165,091,0001,279,031,0001,387,510,0001,092,574,000399,243,000413,247,000
Restricted cash and investments1,319,0001,319,0001,317,0001,318,0001,103,0001,103,000
Other noncurrent assets95,263,00076,276,00064,359,00060,046,00052,690,00046,143,000
Total noncurrent assets:1,589,588,0001,661,540,0001,723,333,0001,345,881,000605,788,000574,233,000
TOTAL ASSETS:3,305,363,0003,378,103,0003,511,318,0003,559,746,0002,087,267,0002,091,305,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities63,628,00046,556,00077,575,00048,972,00032,619,00075,888,000
Accounts payable31,414,00020,514,00048,452,00018,219,00010,466,00021,717,000
Accrued liabilities32,214,00026,042,00029,123,00030,753,00022,153,00054,171,000
Other undisclosed current liabilities90,858,00050,440,00062,605,00074,818,00050,228,00011,216,000
Total current liabilities:154,486,00096,996,000140,180,000123,790,00082,847,00087,104,000
Noncurrent Liabilities
Liabilities, other than long-term debt79,543,00081,081,00065,319,00018,322,00018,288,00020,218,000
Other liabilities   100,000   
Operating lease, liability79,543,00081,081,00065,219,00018,322,00018,288,00020,218,000
Total noncurrent liabilities:79,543,00081,081,00065,319,00018,322,00018,288,00020,218,000
Total liabilities:234,029,000178,077,000205,499,000142,112,000101,135,000107,322,000
Equity
Equity, attributable to parent3,071,334,0003,200,026,0003,305,819,0003,417,634,0001,986,132,0001,983,983,000
Common stock133,000132,000128,000127,000114,000112,000
Additional paid in capital4,768,698,0004,729,253,0004,697,883,0004,668,607,0003,132,318,0003,000,394,000
Accumulated other comprehensive income (loss)(1,887,000)(322,000)(3,873,000)139,0001,815,0002,889,000
Accumulated deficit(1,695,610,000)(1,529,037,000)(1,388,319,000)(1,251,239,000)(1,148,115,000)(1,019,412,000)
Total equity:3,071,334,0003,200,026,0003,305,819,0003,417,634,0001,986,132,0001,983,983,000
TOTAL LIABILITIES AND EQUITY:3,305,363,0003,378,103,0003,511,318,0003,559,746,0002,087,267,0002,091,305,000

Income Statement (P&L) (USD)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Operating expenses(226,219,000)(180,793,000)(162,169,000)(139,924,000)(152,981,000)(114,472,000)
Operating loss:(226,219,000)(180,793,000)(162,169,000)(139,924,000)(152,981,000)(114,472,000)
Nonoperating income59,646,00040,075,00025,089,00036,800,00024,278,00019,452,000
Investment income, nonoperating31,073,00032,935,000    
Other nonoperating income28,573,0007,140,00025,089,00036,800,00024,278,00019,452,000
Net loss available to common stockholders, diluted:(166,573,000)(140,718,000)(137,080,000)(103,124,000)(128,703,000)(95,020,000)

Comprehensive Income (USD)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Net loss:(166,573,000)(140,718,000)(137,080,000)(103,124,000)(128,703,000)(95,020,000)
Comprehensive loss:(166,573,000)(140,718,000)(137,080,000)(103,124,000)(128,703,000)(95,020,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,565,000)3,551,000(4,012,000)(1,676,000)(1,074,000)2,710,000
Comprehensive loss, net of tax, attributable to parent:(168,138,000)(137,167,000)(141,092,000)(104,800,000)(129,777,000)(92,310,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: